Poseida Therapeutics Inc. (PSTX) News
Filter PSTX News Items
PSTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PSTX News Highlights
- For PSTX, its 30 day story count is now at 4.
- Over the past 14 days, the trend for PSTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PSTX are GENE.
Latest PSTX News From Around the Web
Below are the latest news stories about Poseida Therapeutics Inc that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology InnovationsPoseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT. |
Poseida Therapeutics Appoints Brent Warner as President, Gene TherapyPoseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022. |
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers SymposiumPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced interim results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC). These data are being presented today at the 2022 American Society of |
Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 23, 2022. |
Poseida Therapeutics names company''s PresidentPoseida Therapeutics (PSTX) appoints current President and Chief Business Officer, Mark Gergen, to the role of CEO effective as of February 1, 2022 and Eric Ostertag as… |
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark GergenPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Eric Ostertag as Executive Chairman and the transition of current President and Chief Business Officer, Mark Gergen, to the role of Chief Executive Officer effective as of February 1, 2022. The Company also provided a summary business update and 2022 |
Walgreens Boots (WBA) Gains From New Pacts, Faces Margin WoesOf late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly. |
Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI LabelThe latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business. |
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid TumorsPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-MUC1C-ALLO1, the Company's allogeneic CAR-T product candidate targeting multiple solid tumor indications. |
Poseida Therapeutics (NASDAQ:PSTX) Rating Increased to Buy at Zacks Investment ResearchPoseida Therapeutics (NASDAQ:PSTX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. The brokerage presently has a $7.75 target price on the stock. Zacks Investment Researchs target price indicates a potential upside of 15.67% from the stocks current price. According to Zacks, [] |